Alnylam Initiates ENVISION Phase 3 Clinical Study with Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)
Go back to Alnylam Initiates ENVISION Phase 3 Clinical Study with Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 266.11 +1.61 (0.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $264.50 | 52 Week High | $109.10 | |||
| Open | $258.58 | 52 Week Low | $31.38 | |||
| Day High | $266.85 | P/E | N/A | |||
| Day Low | $258.02 | EPS | $-1.45 | |||
| Volume | 1,431,222 | |||||
